Diabetology International

SGLT-2 inhibitor add-on to DPP-4 inhibitor therapy significantly reduces HbA1c and body weight without increasing hypoglycaemia risk in type 2 diabetes inadequately controlled on metformin: a systematic review and meta-analysis

By Arif Saleem, Haris Shinwari, Muhammad Usman, Iftikhar Ahmad

ReviewInterventions

The paper

Arif Saleem, Haris Shinwari, Muhammad Usman, Iftikhar Ahmad

Aga Khan University Hospital; Institute of Radiotherapy and Nuclear Medicine

Diabetology International, 5 Oct 2026

doi.org/10.1007/s13340-026-00934-1 PubMed 42835190

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes